专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100136115A1 Pharmaceutical Titanium Dioxide Composite Allowing Disappearance of Drug Efficacy By Light Irradiation 审中-公开
标题翻译：药物二氧化钛复合物允许通过光照射消除药物功效
公开(公告)号：US20100136115A1
公开(公告)日：2010-06-03
申请号：US11990040
申请日：2006-08-04
申请人： Shuji Sonezaki , Koki Kanehira , Yumi Ogami , Toshiaki Banzai , Yoshinobu Kubota
发明人： Shuji Sonezaki , Koki Kanehira , Yumi Ogami , Toshiaki Banzai , Yoshinobu Kubota
IPC分类号： A61K9/14 , A61K31/704 , A61K38/14 , A61P35/00
CPC分类号： A61K41/0028 , A61K9/0019 , A61K31/704 , A61K47/58 , A61K47/6923 , A61K47/6929 , B82Y5/00
摘要： Disclosed is a titanium dioxide composite material which can be dispersed in an aqueous solvent stably and can be administered to a living body in a simple manner and in which the pharmacological effect of a therapeutic compound carried on the composite material can be eliminated by irradiation with light. Also disclosed is a dispersion product of the composite material. The composite material comprises titanium dioxide which has a photocatalytic activity and a therapeutic compound attached to the titanium dioxide through a hydrophilic polymer. The composite material is stable in an aqueous solvent and can be administered to a living body in a simple manner. After the composite material is administered to a living body, a site on the living body where the pharmacological effect of the therapeutic compound is not needed to be developed can be irradiated with light to induce the light excitation of titanium dioxide at the site, thereby decomposing the therapeutic compound to reduce any adverse side effect of the therapeutic compound.
摘要翻译：公开了一种二氧化钛复合材料，其可以稳定地分散在水性溶剂中，并且可以简单的方式施用于生物体，并且通过照射光可以消除携带在复合材料上的治疗化合物的药理作用。还公开了复合材料的分散体。复合材料包括具有光催化活性的二氧化钛和通过亲水性聚合物连接到二氧化钛上的治疗化合物。复合材料在水性溶剂中稳定，可以以简单的方式施用于生物体。在将复合材料施用于生物体后，可以用光照射生物体上不需要开发治疗化合物的药理作用的部位，从而在该部位诱导二氧化钛的光激发，从而分解该治疗化合物用于减少治疗化合物的任何副作用。

2. 发明申请

US20060281087A1 Titanium dioxide complex having molecule distinguishability 审中-公开
标题翻译：具有分子识别性的二氧化钛络合物
公开(公告)号：US20060281087A1
公开(公告)日：2006-12-14
申请号：US10551164
申请日：2004-03-31
申请人： Shuji Sonezaki , Koki Kanehira , Shinichi Yagi , Yumi Ogami
发明人： Shuji Sonezaki , Koki Kanehira , Shinichi Yagi , Yumi Ogami
IPC分类号： C12Q1/68 , C09C1/36 , G01N33/555
CPC分类号： A61K41/0019 , A61K9/0014 , A61K33/24 , A61K41/0042 , A61K47/02 , A61K47/6883 , A61K47/6923 , A61K47/6929 , A61L2/16 , B82Y5/00 , C07K17/14 , G01N33/554
摘要： A titanium dioxide composite having a molecular recognition capacity is obtained by modifying the surface of a fine titanium dioxide particle with a hydrophilic polymer in such a manner that titanium dioxide is bonded via an ester bond to a carboxyl group of the hydrophilic polymer and immobilizing a molecule having an ability to specifically bind to a target molecule to the carboxyl residue of the hydrophilic polymer. Due to the molecule distinguishability, this titanium dioxide complex can bind specifically to an endocrine disrupting chemical, a pathogenic factor, a cancer cell and the like and decompose the same by a photocatalytic function.
摘要翻译：具有分子识别能力的二氧化钛复合体是通过用亲水性聚合物的羧基与二氧化钛键合而使亲水性聚合物的表面进行改性而得到的，具有将特异性结合到亲水性聚合物的羧基残基的靶分子的能力。由于分子的可区分性，这种二氧化钛络合物可以特异性结合内分泌干扰物，致病因子，癌细胞等，并通过光催化功能分解。

3. 发明授权

US08431143B2 Therapeutic method of administering pharmaceutical titanium dioxide composite and light irradiation 有权
标题翻译：药物二氧化钛复合物和光照射的治疗方法
公开(公告)号：US08431143B2
公开(公告)日：2013-04-30
申请号：US12889753
申请日：2010-09-24
申请人： Shuji Sonezaki , Koki Kanehira , Yumi Ogami , Toshiaki Banzai , Yoshinobu Kubota
发明人： Shuji Sonezaki , Koki Kanehira , Yumi Ogami , Toshiaki Banzai , Yoshinobu Kubota
IPC分类号： A61P33/00 , A61K47/48 , A61K9/00 , A61K9/14 , A61K9/16 , A61K31/70 , A61K9/10 , A61K31/704 , A61K47/02 , A01N25/32 , A01N43/04
CPC分类号： A61K41/0028 , A61K9/0019 , A61K31/704 , A61K47/58 , A61K47/6923 , A61K47/6929 , B82Y5/00
摘要： A titanium dioxide composite is provided that can be stably dispersed in an aqueous solvent and easily administered into a living body, such as human, and allows elimination of the drug efficacy of a pharmaceutical compound supported thereon by light irradiation and a dispersion thereof. A composite is used in which a pharmaceutical compound is bound to titanium dioxide having photocatalytic activity through a hydrophilic polymer. The composite is stable in an aqueous solvent and easily administered into a living body, and adverse drug reactions of the pharmaceutical compound can be reduced by administering the composite into the body and irradiating the composite with a light to photoexcite the titanium dioxide to decompose the pharmaceutical compound in a region where the drug efficacy of the pharmaceutical composition is not required.
摘要翻译：提供二氧化钛复合体，其可以稳定地分散在水性溶剂中，并且容易地施用到人体等生物体中，并且可以通过光照射及其分散来消除其上负载的药物化合物的药物功效。使用其中药物化合物通过亲水性聚合物与具有光催化活性的二氧化钛结合的复合物。该复合材料在水性溶剂中稳定，容易投入生物体中，通过将复合体投入体内照射复合体，对该复合体进行光照射，可以降低药物化合物的药物不良反应，使二氧化钛分解，在不需要药物组合物的药物功效的区域中的化合物。

4. 发明授权

US08071332B2 Recombinant mammal cells, method of producing thereof, and method of producing proteins of interest 有权
标题翻译：重组哺乳动物细胞，其制备方法，以及产生感兴趣蛋白质的方法
公开(公告)号：US08071332B2
公开(公告)日：2011-12-06
申请号：US12222412
申请日：2008-08-08
申请人： Toshiaki Banzai , Yukiko Koyama , Shuji Sonezaki
发明人： Toshiaki Banzai , Yukiko Koyama , Shuji Sonezaki
IPC分类号： C12P21/06 , C12N5/00
CPC分类号： C12P21/02
摘要： The present invention relates to a method of expressing an objective protein at a high level and stably as well as for a long period even in the absence of a selection drug with a recombinant mammal cell. More particularly, the present invention relates to a method of producing an objective protein by providing a recombinant mammal cell having multiple copies of the exogenous objective protein gene expression unit integrated into a hypoxanthine-phosphoribosyl transferase enzyme (hprt) gene locus and culturing said cell.
摘要翻译：本发明涉及一种以高水平，稳定以及长时间表达目的蛋白的方法，即使在不存在用重组哺乳动物细胞的选择药物的情况下。更具体地说，本发明涉及一种通过提供具有多个拷贝的外源目的蛋白质基因表达单元的重组哺乳动物细胞来生产目的蛋白质的方法，所述外源目的蛋白质基因表达单元整合到次黄嘌呤 - 磷酸核糖基转移酶（hprt）基因座中并培养所述细胞。

5. 发明申请

US20110137235A1 ULTRASONIC CANCER THERAPY ACCELERATOR 审中-公开
标题翻译：超声波治疗加速器
公开(公告)号：US20110137235A1
公开(公告)日：2011-06-09
申请号：US13057858
申请日：2009-08-07
申请人： Koki Kanehira , Shuji Sonezaki , Yumi Ogami , Toshiaki Banzai , Tomomi Nakamura
发明人： Koki Kanehira , Shuji Sonezaki , Yumi Ogami , Toshiaki Banzai , Tomomi Nakamura
IPC分类号： A61M37/00 , C07F7/28 , C07F19/00 , C12N13/00 , A61K31/28 , A61P35/00
CPC分类号： A61K41/0033 , A61K31/28 , A61K47/6923 , Y10T428/2982
摘要： Provided is an ultrasonic cancer therapy accelerator comprising titanium oxide-metal complex particles showing a long-lasting antitumor effect imparted thereto while sustaining the dispersibility and catalytic activity thereof which are obtained by dispersing titanium oxide-metal complex particles in an aqueous solvent with the use of a water-soluble polymer and modifying the same with molecules containing a low-valent transition metal via linker molecules having been bound thereto without denaturing the water-soluble polymer. To the titanium oxide surface of titanium oxide-metal complex particles which have been dispersed in an aqueous solvent with the use of a water-soluble polymer, linker molecules are bound via at least one functional group selected from the group consisting of carboxyl, amino, diol, salicylate and phosphate groups followed by the modification with low-valent transition metal-containing molecules via the linker molecules. Thus, an ultrasonic cancer therapy accelerator, which comprises titanium oxide-metal complex particles showing a long-lasting antitumor effect imparted thereto while sustaining the dispersibility and catalytic activity thereof, can be provided. This ultrasonic cancer therapy accelerator, which accumulates in an affected area, can be used as a drug for therapy combined with ultrasonic irradiation.
摘要翻译：本发明提供一种包含氧化钛 - 金属络合物颗粒的超声波治疗促进剂，其表现出赋予其持久的抗肿瘤效果，同时维持其分散性和催化活性，其通过将氧化钛 - 金属络合物颗粒分散在水性溶剂中而获得，水溶性聚合物，并通过已经结合到其上的连接分子将其与含有低价过渡金属的分子进行改性而不变性水溶性聚合物。通过使用水溶性聚合物分散在水性溶剂中的氧化钛 - 金属络合物颗粒的氧化钛表面，通过至少一种选自羧基，氨基，二醇，水杨酸酯和磷酸酯基，然后通过连接分子用低价含过渡金属的分子进行修饰。因此，可以提供包含表现出持久的抗肿瘤作用的氧化钛 - 金属络合物颗粒，同时维持其分散性和催化活性的超声波癌症治疗促进剂。积聚在受影响区域的超声波治疗加速器可以用作与超声波照射联合治疗的药物。

6. 发明申请

US20090297620A1 Anti-Tumor Agent 审中-公开
标题翻译：抗肿瘤剂
公开(公告)号：US20090297620A1
公开(公告)日：2009-12-03
申请号：US12384664
申请日：2009-04-07
申请人： Koki Kanehira , Shuji Sonezaki , Yumi Ogami , Tomomi Nakamura , Toshiaki Banzai
发明人： Koki Kanehira , Shuji Sonezaki , Yumi Ogami , Tomomi Nakamura , Toshiaki Banzai
IPC分类号： A61K9/14 , C07K16/00 , A61K39/395
CPC分类号： B82Y5/00 , A61K47/58 , A61K47/60 , A61K47/6843 , A61K47/6923
摘要： Titanium oxide-antibody conjugated particles are disclosed, which are provided with selective binding ability without loss of dispersibility and catalytic activity by modifying titanium oxide conjugated particles, dispersed in a water-based solvent by a water-soluble polymer, with an antibody via a linker molecule bound without changing the nature of the water-soluble polymer. The present invention is an antitumor agent, comprising titanium oxide-antibody conjugated particles, wherein a linker molecule is bound to the titanium oxide surface of the titanium oxide conjugated particles, dispersed in a water-based solvent by a water-soluble polymer, via at least one functional group selected from a group consisting of a carboxyl group, an amino group, a diol group, a salicylic acid group, and a phosphoric acid group, and wherein the titanium oxide conjugated particles are further modified with an antibody via the linker molecule. This antitumor agent is concentrated in the affected area and can be utilized as an agent for diagnosis or for treatment in combination with ultrasonic irradiation.
摘要翻译：公开了氧化钛 - 抗体共轭颗粒，其具有选择性结合能力，而不丧失分散性和催化活性，通过经由接头将抗体通过用水溶性聚合物改性分散在水基溶剂中的氧化钛共轭颗粒分子结合而不改变水溶性聚合物的性质。本发明是一种抗氧化剂 - 抗体共轭颗粒的抗肿瘤剂，其中连接分子通过水溶性聚合物通过水溶性聚合物与氧化钛共轭颗粒的氧化钛表面结合，分散在水基溶剂中至少一个选自羧基，氨基，二醇基，水杨酸基和磷酸基的官能团，并且其中所述氧化钛共轭颗粒通过所述连接分子被抗体进一步修饰。该抗肿瘤药物集中在受影响的区域，可用于诊断或与超声波照射相结合的治疗剂。

7. 发明申请

US20090205979A1 Electrolyte-Containing Sheet For Use In Specific Detection Of Analyte Using Photocurrent 审中-公开
标题翻译：用于特定检测使用光电流的分析物的含电解质片
公开(公告)号：US20090205979A1
公开(公告)日：2009-08-20
申请号：US12348993
申请日：2009-01-06
申请人： Makoto Bekki , Hitoshi Ohara , Shuji Sonezaki , Yoshimasa Yamana
发明人： Makoto Bekki , Hitoshi Ohara , Shuji Sonezaki , Yoshimasa Yamana
IPC分类号： G01N27/26 , G01F1/64 , C25B11/00 , C25B9/00
CPC分类号： G01N27/305
摘要： There is disclosed an electrolyte medium which makes it possible to significantly simplify device structure and detection procedure as well as to detect photocurrent with high sensitivity and accuracy, in specific detection of an analyte with use of photocurrent generated by photo-excitation of a sensitizing dye. The electrolyte-containing sheet comprises a hydrous substrate; and an electrolyte contained in the hydrous substrate. The electrolyte-containing sheet is used as an electrolyte medium in specific detection of an analyte with use of photocurrent generated by photo-excitation of a sensitizing dye. A gel matrix or a water-absorbent substrate can be used as the hydrous substrate.
摘要翻译：公开了一种电解质介质，其可以通过使用通过感光染料的光激发产生的光电流来特异性检测分析物，从而显着简化器件结构和检测过程以及以高灵敏度和精确度检测光电流。含电解质的片材包含含水基材; 以及包含在含水基材中的电解质。含电解质的片材用作特定检测分析物的电解质介质，其使用通过感光染料的光激发产生的光电流。可以使用凝胶基质或吸水性基质作为含水底物。

8. 发明申请

US20090117615A1 Recombinant mammal cells, method of producing thereof, and method of producing proteins of interest 有权
标题翻译：重组哺乳动物细胞，其制备方法，以及产生感兴趣蛋白质的方法
公开(公告)号：US20090117615A1
公开(公告)日：2009-05-07
申请号：US12222412
申请日：2008-08-08
申请人： Toshiaki Banzai , Yukiko Koyama , Shuji Sonezaki
发明人： Toshiaki Banzai , Yukiko Koyama , Shuji Sonezaki
IPC分类号： C12P21/00 , C12N5/10 , C12N15/09
CPC分类号： C12P21/02
摘要： The present invention relates to a method of expressing an objective protein at a high level and stably as well as for a long period even in the absence of a selection drug with a recombinant mammal cell. More particularly, the present invention relates to a method of producing an objective protein by providing a recombinant mammal cell having multiple copies of the exogenous objective protein gene expression unit integrated into a hypoxanthine-phosphoribosyl transferase enzyme (hprt) gene locus and culturing said cell.
摘要翻译：本发明涉及一种以高水平，稳定以及长时间表达目的蛋白的方法，即使在不存在用重组哺乳动物细胞的选择药物的情况下。更具体地说，本发明涉及一种通过提供具有多个拷贝的外源目的蛋白质基因表达单元的重组哺乳动物细胞来生产目的蛋白质的方法，所述外源目的蛋白质基因表达单元整合到次黄嘌呤 - 磷酸核糖基转移酶（hprt）基因座中并培养所述细胞。

9. 发明授权

US08992958B2 Ultrasonic cancer treatment enhancer and cell killer 有权
标题翻译：超声波癌症治疗增强剂和细胞杀伤剂
公开(公告)号：US08992958B2
公开(公告)日：2015-03-31
申请号：US11883208
申请日：2006-10-26
申请人： Koki Kanehira , Shuji Sonezaki , Yumi Ogami , Toshiaki Banzai
发明人： Koki Kanehira , Shuji Sonezaki , Yumi Ogami , Toshiaki Banzai
IPC分类号： A61N7/00 , A61K33/30 , A61K33/24 , A61K41/00 , B82Y5/00 , A61K9/00 , A61K9/19
CPC分类号： A61K33/30 , A61K9/0019 , A61K9/19 , A61K33/24 , A61K41/0033 , B82Y5/00
摘要： There is provided an ultrasonic cancer treatment enhancer and cell killer that can significantly improve the effect of treating cancer by ultrasonic irradiation while ensuring a high level of safety. The ultrasonic cancer treatment enhancer and cell killer comprise metal semiconductor particles and can be activated upon ultrasonic irradiation to kill or destruct cancer cells.
摘要翻译：提供超声波治疗增强剂和细胞杀伤剂，其可以通过超声波照射显着改善治疗癌症的效果，同时确保高水平的安全性。超声波治疗增强剂和细胞杀伤剂包含金属半导体颗粒，并且可以在超声波照射下被激活以杀死或破坏癌细胞。

10. 发明申请

US20110060269A1 METHOD FOR KILLING CELLS USING PHOTOCATALYTIC TITANIUM DIOXIDE PARTICLES 审中-公开
标题翻译：使用光催化二氧化钛颗粒杀死细胞的方法
公开(公告)号：US20110060269A1
公开(公告)日：2011-03-10
申请号：US12943165
申请日：2010-11-10
申请人： Koki KANEHIRA , Shuji SONEZAKI , Yumi OGAMI , Toshiaki BANZAI , Junji KAMESHIMA
发明人： Koki KANEHIRA , Shuji SONEZAKI , Yumi OGAMI , Toshiaki BANZAI , Junji KAMESHIMA
IPC分类号： A61M37/00
CPC分类号： A61K9/5146 , A61K9/1676 , A61K33/24 , A61K41/0042 , B01J21/063 , B01J35/0013 , B01J35/004 , B82Y30/00 , C01G23/047 , C01P2002/84 , C01P2004/64 , C09C1/3676
摘要： Photocatalytic titanium dioxide particles are disclosed having improved dispersibility into an aqueous solvent not only under neutral physiological conditions in vivo but also over a wide pH range, and improved cell affinity and cell uptake property. The photocatalytic titanium dioxide particles comprise particles comprising photocatalytic titanium dioxide and a cationic hydrophilic polymer modifying surfaces of the photocatalytic titanium dioxide particles, wherein the hydrophilic polymer is bonded to the photocatalytic titanium dioxide particles. The particles are very useful for medical applications, such as destruction of cancer cells, e.g., when administered to a mammal the titanium dioxide particles are taken up by cells of the mammal, and if then irradiated with UV light the particles kill the cells via photocatalytic degrading capability.
摘要翻译：公开了光催化二氧化钛颗粒，其不仅在体内中性生理条件下而且在宽pH范围内都具有改进的水溶剂分散性，并且改善了细胞亲和力和细胞摄取性能。光催化二氧化钛颗粒包含包含光催化二氧化钛和光催化二氧化钛颗粒的阳离子亲水聚合物改性表面的颗粒，其中亲水性聚合物与光催化二氧化钛颗粒结合。这些颗粒对于医疗应用非常有用，例如癌细胞的破坏，例如当向哺乳动物施用二氧化钛颗粒被哺乳动物的细胞吸收时，如果然后用UV光照射，则颗粒通过光催化剂杀死细胞降级能力

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式